TABLE 2

Hematologic Data Related to 131I Therapies

DateHemoglobin (g/dL)Leukocytes (1,000/μL)Neutrophils (1,000/μL)Platelets (1,000/μL)131I treatment (GBq)Other treatment
Patient 1
    Jan-981163.32281.85
    Feb-9812.14.7159Antithyroid drug
    Apr-9810.13.72.51862.59
    May-9810.43.32.4241Antithyroid drug
    Sep/Oct-9810.44.232013.15
    Nov-9811.63.12.2160Thyroxine
    Jan-9911.23.72.51845.7
    Mar-999.82.51.7150Thyroxine
    Jul-9910.23.82.31764.8
    Aug-999.82.31.773Thyroxine
    Sep-997.21.91.259Thyroxine plus transfusion of 2 units
    Dec-999.62.81.7108Thyroxine
    Mar-001031.8144Thyroxine
Patient 2
    Dec-97113.92.33722.2Begin thyroxine
    Jan-9811.34383Continue thyroxine
    Sep-989.63.82.62814.6Restart thyroxine
    Nov-989.83.22287Continue thyroxine
    Feb-0010.44.93.6302Stop thyroxine
    Mar-009.92.91.72675.6Restart thyroxine at 0.137 mg/d
    Apr-009.62.11.2195Continue thyroxine
  • Hematologic indices were obtained just before and 5–6 wk after 131I therapies except as noted; additional measurements were made but did not show marked differences.